StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Performance
Shares of LPCN opened at $3.44 on Thursday. The stock has a fifty day moving average price of $4.13 and a two-hundred day moving average price of $4.54. Lipocine has a 52-week low of $2.91 and a 52-week high of $11.79. The company has a market cap of $18.40 million, a price-to-earnings ratio of -4.53 and a beta of 1.23.
Institutional Investors Weigh In On Lipocine
An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its position in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is currently owned by hedge funds and other institutional investors.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- What is the MACD Indicator and How to Use it in Your Trading
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
